Sunovion Pharmaceuticals Inc. is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. The company’s vision is to lead the way to a healthier world, and believes scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions. Sunovion is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. For more information, visit www.sunovion.com.
Sumitomo Dainippon Pharma Oncology, Inc. (SDP Oncology) is a clinical-stage company and developer of novel cancer therapeutics based in the U.S. and a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. SDP Oncology leverages their passion for challenging work to collaborate across geographies and realize a common goal—advancing purposeful science by transforming new discoveries into meaningful therapeutic options for patients with cancer. SDP Oncology, Inc. was formed on July 1, 2020 through the merger of Tolero Pharmaceuticals, Inc., and Boston Biomedical, Inc. For more information, visit www.sdponcology.com.
Sumitovant is a global biopharmaceutical company, the majority shareholder of Myovant and Urovant, and wholly owns Enzyvant, Spirovant and Altavant. Sumitovant’s promising pipeline is comprised of early-through late-stage investigational medicines across a range of disease areas targeting high unmet need. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. For more information, visit www.sumitovant.com.